Gilead Chooses Middle Ground in Pricing of Its Coronavirus Drug
A person enters a building at Gilead Sciences Inc. headquarters in Foster City, California, U.S. (Photographer: David Paul Morris/Bloomberg)

Gilead Chooses Middle Ground in Pricing of Its Coronavirus Drug

(Bloomberg) -- Gilead Sciences Inc. said that it will charge U.S. hospitals roughly $3,120 for most patients who need remdesivir, picking a middle ground in a high-profile decision on the cost of o...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.